← Back to patent-cliff list
阿托伐他汀钙水合物
Tier C — Watch / tradeAtorvastatin Calcium Hydrate
辉瑞
Originator
1996
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HMGCR
Brand：Safestat、Torvast、Lipitor、Tahor、Tulip、Kolevas、Prevencor、Lipibec、Sortis、立普妥
Indications (approved)：高脂蛋白血症Ⅲ型、高脂血症、杂合子家族性高胆固醇血症、心脏衰竭、二型糖尿病、中风、冠状动脉疾病、心肌梗塞
Regional status
US
批准上市
1996-12-17
EU
临床三期
2003-01-01
China
批准上市
1999-01-01
Japan
批准上市
2000-03-10
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Atorvastatin Calcium Hydrate?
Approved indications include: 高脂蛋白血症Ⅲ型, 高脂血症, 杂合子家族性高胆固醇血症, 心脏衰竭, 二型糖尿病, 中风, 冠状动脉疾病, 心肌梗塞.
When does the Atorvastatin Calcium Hydrate patent expire?
No public expiry year is available for Atorvastatin Calcium Hydrate yet; this page updates once verified.
How do I get a quote for Atorvastatin Calcium Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25